The story isn't M&A. It's capital raising

The most significant development in biotech isn't overall transaction volume. It's the changing composition of that activity.

Capital raising has now surpassed M&A as the dominant form of deal activity, accounting for 53% of trailing twelve-month projects and growing 25% year over year. In contrast, asset sales remained relatively stable, increasing by roughly 7%, while mergers declined by 10%.

This shift challenges the narrative that biotech is entering a straightforward consolidation cycle. Instead, the data suggests a fundraising-driven market in which companies are actively seeking capital while exploring a wider range of financing options.

Alternative financing is driving growth

A closer look at fundraising activity reveals an even more compelling trend.

Traditional venture capital funding rounds declined nearly 15% year over year. Meanwhile, several alternative financing structures experienced substantial growth:

• Structured and alternative financing increased 76%
• IPO and listing activity rose 43%
• Refinancing and recapitalization activity doubled

The takeaway is clear: this is not a story of venture capital returning to previous highs. Rather, biotech companies are adapting to a more challenging funding landscape by diversifying how they access capital.

For founders, investment bankers, and corporate development professionals, this signals a market that rewards creativity, flexibility, and strategic financial planning.

Corporate buyers are taking the lead

The composition of market participants is shifting as well.

Datasite data suggests strategic and corporate players are becoming increasingly active across the biotech landscape. Whether pursuing fundraising initiatives, exploring partnerships, or evaluating acquisition opportunities, corporate participants appear to be playing a more prominent role than financial sponsors.

This trend points to a market where strategic alignment and long-term growth objectives may be becoming more important drivers of activity than purely financial considerations.

Regional dynamics continue to evolve

Geography remains an important factor in biotech deal activity.

The Northeast continues to serve as the sector's foundation, led by the Boston and Cambridge innovation ecosystem. California also remains a major center of activity, reflecting the continued strength of its life sciences and biotechnology communities.

However, the industry's fastest growth is occurring elsewhere.

The Southern United States experienced a 56% year-over-year increase in activity, fueled by growth in markets such as:

• Florida
• Virginia
• North Carolina
• Texas

By comparison, activity in the Midwest declined 55% over the same period.

These trends suggest a two-speed market. Established biotech hubs in the Northeast and California continue to provide scale, talent, and credibility, while emerging markets across the Sun Belt are generating increasing momentum and attracting new investment.

Why readiness matters more than ever

Perhaps the most important lesson from the data is that biotech's recovery is not following a traditional path.

The sector is increasingly characterized by:

• Fundraising-led activity rather than M&A-driven expansion
• Greater reliance on alternative financing structures
• Increased involvement from corporate and strategic players
• Longer preparation timelines and greater emphasis on diligence readiness

Capital remains available, but investors and acquirers are being highly selective. In this environment, organizations that can clearly articulate their growth story, maintain organized diligence processes, and respond quickly to opportunity will be best positioned to succeed.

Looking ahead

Biotech deal activity across the Americas is moving in a positive direction, but market participants should not expect a simple return to previous cycles.

Instead, the sector is entering a new phase defined by evolving financing strategies, increased corporate participation, and a growing emphasis on preparedness. For dealmakers, success will depend not only on identifying opportunities, but also on being ready to move with confidence when those opportunities arise.

As the market continues to develop, one thing is clear: the companies best equipped to navigate complexity will be the ones most likely to capitalize on biotech's next wave of growth.

Watch the full video here.